New ALS Chip Model Closely Mimics Disease, May Aid Research
Researchers report having created a new human-on-a-chip model, one able to more accurately simulate the clinical features of amyotrophic…
Articles by Patricia Inácio, PhD
Clinigen’s Aldesleukin Earns FDA’s Orphan Drug Designation as ALS Treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Clinigen’s aldesleukin for the treatment of…
ALS Patients Show Altered Levels of Iron Status Indicators, Study Reports
The levels of certain indicators of iron status, namely ferritin and transferrin, are altered in patients with…
Results of Phase 3 Trial of NurOwn Cell Therapy Expected by End of Year
The pivotal Phase 3 clinical trial testing BrainStorm Cell Therapeutic’s cell-based therapy NurOwn in amyotrophic lateral sclerosis…
Funding to Boost Clinical Development of Investigational ALS Therapy ILB
Tikomed has secured $5.5 million in financing from investors to support the ongoing clinical development of ILB, its lead therapy…
Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
Reldesemtiv Wins EMA Orphan Drug Designation for ALS Treatment
The European Medicines Agency (EMA) granted orphan drug status to Cytokinetics‘ reldesemtiv for the treatment of …
Alexion to Initiate Phase 3 Trial of Ultomiris for Familiar, Sporadic ALS Patients
In the coming months, Alexion Pharmaceuticals will launch a pivotal Phase 3 clinical trial to test its complement system inhibitor…
Reldesemtiv Earns FDA’s Orphan Drug Designation for ALS Treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Cytokinetics and Astellas Pharma‘s…
FDA Approves Dosing Tiglutik Via Feeding Tube for ALS Patients
The U.S. Food and Drug Administration has agreed to expand Tiglutik, a liquid oral form of riluzole,…